UAE To Trial Sinopharm in Children From 3 to 12

Publish date: Tuesday، 18 January 2022

Under the supervision of the Ministry of Health and Prevention (MOHAP), the UAE has begun to trial the Sinopharm COVID-19 vaccine in children aged 3 to 17 to study the impact on their immune system.

The study has been approved by the Department of Health – Abu Dhabi. The capital media office said that the study will monitor the immune response to the vaccine in 900 children of different nationalities.

The Ministry of Health and Prevention has begun a Sinopharm immune bridge study for children, following the vaccine’s effectiveness in reducing the infection rate and severity of symptoms among target groups. pic.twitter.com/RjEOL2QtFs
— مكتب أبوظبي الإعلامي (@admediaoffice) June 10, 2021

Dr Nawal Al Kaabi, Chairwoman of the National COVID-19 Clinical Management Committee, who is leading the study, explained that the Sinopharm immune bridge study has been designed to ensure "children are able to receive the vaccine safely".

Each child will participate with the full consent of their parents and will be closely monitored at every step of the process.

The authorities added that it's a significant step in combating the pandemic and will support the planning process for the safe return to schools.

The study’s preliminary results will be announced "once available".

Image Credit: Unsplash

This article was previously published on UAE Moments.To see the original article, click here

To read the full story for free, please enter your e-mail

Thank you for your subscription, you will receive our Newsletter shortly

UAE To Trial Sinopharm in Children From 3 to 12

Related articles